Related Experiment Videos
Are 5-hydroxytryptamine-3 receptor antagonists efficient antiemetics for chemotherapy-induced delayed emesis and do
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648.
Annals of oncology : official journal of the European Society for Medical Oncology·2026
Twenty-year survival of advanced gastrointestinal stromal tumours treated with imatinib: exploratory long-term follow-up of the BFR14 trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2025
Tackling a worrisome rate of lost to follow-up among migrants with hepatitis B in French Guiana.
Infectious diseases now·2024
A randomized study of 6 versus 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse.
Annals of oncology : official journal of the European Society for Medical Oncology·2024
Scabies in French Guiana: Quantitative and qualitative factors associated with therapeutic failure.
Journal of the European Academy of Dermatology and Venereology : JEADV·2023
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
LymphGen-Sig: Integrating Genetic and Transcriptional States to Predict Therapeutic Response in Diffuse Large B-Cell Lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Risk-Adapted Optimization of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2-Positive Early-Stage Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Personalized Circulating Tumor DNA Analysis for Predicting Outcomes and Tracking Response to Radiotherapy and Pembrolizumab in Localized Sarcomas: Analysis of the SU2C-SARC032 Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026